Navigation Links
Bunge Limited to Expand Sugar and Bioenergy Business in Brazil
Date:12/24/2009

WHITE PLAINS, N.Y., Dec. 24 /PRNewswire-FirstCall/ -- Bunge Limited ("Bunge") (NYSE: BG) today announced that it has entered into an agreement to become the 100% owner of Usina Moema Participacoes S.A. ("Moema Par"). Moema Par is a holding company that wholly owns one sugarcane mill in Brazil and has ownership interests in five others. Together, the cluster of six mills ("Moema Group") has an annual crushing capacity of 15.4 million metric tons. With this transaction, Bunge will have a 60% effective share of the total capacity, representing Moema Par's wholly owned mill and its interests in four of the five other mills.

The transaction will be structured as a share exchange, and under the terms of the agreement, shareholders in Moema Par will be entitled to receive approximately 7.3 million common shares of Bunge Limited, which includes a payment of approximately $36 million in respect of working capital. Based on yesterday's closing price of Bunge's common shares, the value of the transaction is approximately $896 million, including approximately $480 million of net debt and excluding this working capital amount. The final number of shares to be issued will be based on the amount of net indebtedness and working capital of Moema Par at closing.

In the coming weeks, Bunge may enter into agreements to secure some or all of the remaining interests in the mills that constitute the Moema Group. These transactions would be on economic terms consistent with the Moema Par transaction.

If, in addition to completing the Moema Par transaction, Bunge secures 100% of the remaining outstanding interests in the Moema Group mills, shareholders in Moema Par and other shareholders in the mills would receive a total of approximately 13.4 million common shares of Bunge Limited, which includes a payment of approximately $60 mi
'/>"/>

SOURCE Bunge Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Bunge Reports Fourth Quarter Net Income of $245 Million
2. Bunge Limited Schedules Third Quarter 2008 Earnings Release and Conference Call
3. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
4. Sunrise Biotech Holding Limited Application For Admission to PLUS
5. Daval International Limited Gains Approval for Phase IIB Trial of AIMSPRO(R)
6. Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement
7. Limited transparency in federal nanotech research may hamper development
8. Application for Listing of Shire Limited Ordinary Shares
9. Non-Safety-Related Voluntary Recall of a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches Announced
10. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
11. EnrichMap Announces New Program To Reduce Medical Patient Noncompliance And Offers Healthcare Organizations A Limited Trial Test Opportunity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/jspg2c/global_biologics ... "Global Biologics and Biosimilars Industry Report 2015" ... The Global Biologics and Biosimilars Industry Report 2015 ... current state of the biologics and biosimilars industry. ... of the industry including definitions, classifications, applications and ...
(Date:3/4/2015)... 04, 2015 PRC Clinical, ... San Francisco Bay Area, will exhibit and present at ... 2015 on March 25th and 26th in Tel ... relationships with Israeli life science companies seeking to conduct ... company’s services span all phases of human trials, from ...
(Date:3/4/2015)... , March 4, 2015 AcelRx Pharmaceuticals, ... pharmaceutical company focused on the development and commercialization ... and breakthrough pain, today announced that it will ... after market close on Monday, March 9th, 2015. ... at 4:30 p.m. Eastern Time (1:30 p.m. Pacific ...
(Date:3/4/2015)... Vegalab announced the acquisition of Ecowin, a ... As part of the acquisition, Ecowin rebranded itself as ... role as CEO for the company,s Korea operations. ... alongside Koo and oversee developments at the new location. ... Koo founded Ecowin in 2008 to great ...
Breaking Biology Technology:Global Biologics and Biosimilars Industry Report 2015-2020 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3
... ,II. Product Components ,III. Materials to be ... of DNA from Whole Blood ,V. Protocol for ... Quantification of Amplified Products ,VII. Purification of Amplified ... , Contact Information , , , , ...
... Using siRNA for gene silencing is a, ... for preparing siRNA, such as chemical synthesis, in vitro transcription, ... cassettes. Irrespective, of which method ... to choose the siRNA target site. The guidelines below for choosing, ...
... , , ... , , This Application Note describes ... total RNA and fragmented cRNA by using,the Agilent 2100 bioanalyzer. The Eukaryote ... 28S/18S ratio in the,total RNA as well as detection of possible degradation. ...
Cached Biology Technology:Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 2Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 3Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 4Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 5Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 6siRNA Design Guidelines 2siRNA Design Guidelines 3siRNA Design Guidelines 4siRNA Design Guidelines 5siRNA Design Guidelines 6siRNA Design Guidelines 7Advancing the quality control methodology,to assess isolated total RNA,and generated fragmented cRNA 2Advancing the quality control methodology,to assess isolated total RNA,and generated fragmented cRNA 3Advancing the quality control methodology,to assess isolated total RNA,and generated fragmented cRNA 4Advancing the quality control methodology,to assess isolated total RNA,and generated fragmented cRNA 5Advancing the quality control methodology,to assess isolated total RNA,and generated fragmented cRNA 6
(Date:1/22/2015)... Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), ... crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz ... production capacity to meet customer demand. ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by ...
(Date:1/22/2015)... WINSTON-SALEM, N.C. , Jan. 16, 2015  A man-made ... working memory and other mental capabilities in adults with ... a pilot study led by researchers at Wake Forest ... 60 adults diagnosed with amnesic mild cognitive impairment (MCI) ...
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small ... Brands report showed that planet-wide, transactions at merchants on the ... the total number of credit, debit, and prepaid cards reached ... were victims of fraudulent card usage in 2012, and credit ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... and Workgroup Scanners Recognized by ... the Leading Guide for Office ... Fujitsu Computer Products of,America, Inc., a market leader in ... scanners earned the "Editor,s Choice",designation in the Better Buys ...
... Bacteria save energy by producing proteins that moonlight, having ... the microbes from being killed. The moonlighting activity of ... resistant to a family of broad-spectrum antibiotics, according to ... journal Microbiology. "Glutamate racemase, or ...
... 2008The many recent reports documenting the therapeutic efficacy of ... disease may actually be describing non-specific therapeutic effects related ... response, according to a paper in the September 2008 ... Therapy , a peer-reviewed journal published by Mary Ann ...
Cached Biology News:Fujitsu Scanners Selected as 'Editor's Choice' in Better Buys for Business 2008 Scan-to-File Guide 2Fujitsu Scanners Selected as 'Editor's Choice' in Better Buys for Business 2008 Scan-to-File Guide 3Energy-saving bacteria resist antibiotics 2Previous claims of siRNA therapeutic effects called into question by report in human gene therapy 2
... quadrupole 1200L sets the new standard ... - incorporating the latest technologies and ... chromatography analytical needs. The Atmospheric ... Transmission Quadrupole Analyzer provide superior selectivity ...
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Catalase (Control)...
Human RELT/TNFRSF19L Affinity Purified Polyclonal Ab...
Biology Products: